Research
    Zhang Lanjun
    Title Professor, Director of Department of Thoracic Surgery, Chief for Thoracic Surgery and National Key Clinical Specialty
    Profile

    Prof. Lanjun Zhang obtained his M.D. in 1984 and his Master in Cardio-Thoracic Surgery in 1990 from The Fourth Military Medical University. From 2001 to 2004, he conducted his research in the field of artificial bio-materials esophagus in Sun Yat-sen University Cancer Center and he obtained his Ph.D in Clinical Oncology. He completed his medical residency in The First Affiliate Hospital of Fourth Military Medical University in China. After attending physician in cardio-thoracic surgery and oncology in Xian and Guangzhou, he has spent his entire training in thoracic oncology at SYSUCC, Sun Yat-sen University, Guangzhou. He was appointed the Director of Thoracic surgery Department in 2010. Under his leadership, the department has been honored The State Key Department by Ministry of Health in 2011.  Professor Zhang is also vice chairman of Lung Cancer Union of Western China and Vice chairman of Trauma Professional Committee in Thoracic Surgery of Chinese medical doctor Association, and member of Tumor Reconstruction Committee of Plastic Surgery Branch of Chinese Medical Association as well.

    Professor Zhang focuses his study either on clinical or basic research, including lung cancer, esophageal cancer, tumor biomarkers investigation, Prognostic factors and treatment stratification, and target therapy. He is also an expert in the reconstruction with artificial bio-materials organs. The patent of his artificial esophagus was awarded in 2001. He is also involved in numerous review committees of journals, funds and diverse expertise in China and internationally.

    He has published over 35 articles during the last ten years in peer-reviewed scientific journals, including J Clin Oncol, Eur J Cardiothorac Surg , BMC Cancer, Ann Oncol, Cancer Genet Cytogenet.

    Email zhanglj@sysucc.org.cn
    Phone
    Research Interest(s)

    1. Surgical treatment for thoracic tumor

    2. Innovation diagnosis for early stage lung cancer

    3. Screening of molecular biomarker in individual treatment for lung cancer

    4. Clinical application of artificial organs

    5. Reconstruction for artificial chest wall following wide tumor resection

    6. Application for surgical reconstruction with artificial esophagus

    7. Management for tumor bank and tumor information plate

    Education

    1984: Graduated from the Fourth Military Medical University and was conferred upon the degree of Bachelor of Medicine;

    1986: Studied cardiac surgery at Royal Children's Hospital of Melbourne;

    1991: Graduated from the Fourth Military Medical University and was conferred upon the degree of Master of Medicine;

    2004: Graduated from Sun Yat-sen University and was conferred upon the degree of Doctor of Medicine.

    Publications

    1. Cai L, Zhu JF, Zhang XW, Lin SX, Su XD, Lin P, Chen K, Zhang LJ. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J Neurooncol. 2014 Nov;120(2):423-30.

    2. Wen YS;Cai L;Zhang XW;Zhu JF;Zhang ZC;Shao JY;Zhang LJ. Concurrent oncogene mutation profile in chinese patients with stage ib lung adenocarcinoma. Medicine _ Volume 00, Number 00, Month 2014

    3. Mahmut Ozsahin, René-Olivier Mirimanoff, Juliette Thariat, Xu Shan Sun, Banu Atalar, Yasmin Lassen-Ramshad, Gamze Ugurluer, Sunil Krishnan, Christopher Hallemeier, Paul Van Houtte, Marco Krengli, Lan Jun Zhang, Kenneth Chang, Ryan Funk, Jessica Rooney, Robert C. Miller. The Rare Cancer Network: Ongoing Studies and Future Strategy. Rare Tumors. 2014 July 30; 6(3): 5465.

    4.  Zhu JF, Feng XY, Zhang XW, Wen YS, Lin P, Rong TH, Cai L, Zhang LJ.Time-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 Chinese patients. PLoS One. 2014 Sep 9;9(9):e106668.

    5. Jianfei Zhu, Ling Cai, Haoxian Yang, Yinsheng Wen, Junye Wang, Tiehua Rong, Jianyong Shao , Lanjun Zhang. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma. Thoracic Cancer 5 (2014) 411–416.

    6. Jian-Fei Zhu, Ling Cai, Xue-Wen Zhang, Yin-Sheng Wen, Xiao-Dong Su, Tie-Hua Rong, Lan-Jun Zhang. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases. Chin J Cancer; 2014; Vol. 33 Issue 2: 96-104.

    7. Dong-Rong Situ, Philippe Dartevelle, Thierry Le Chevalier, Lan-Jun Zhang. The Sino-French 2012 Conference in Thoracic Oncology: an international academic platform for in-depth exchange on comprehensive research. Chin J Cancer. 2013 February; 32(2): 53-58

    8. Yu-Zhen Zheng, Shu-Qin Dai, Wei Li, Xun Cao, Xin Wang, Jian-Hua Fu, Peng Lin, Lan-Jun Zhang, Bin Lu, Jun-Ye Wang. Comparison between different reconstruction routes in esophageal squamous cell carcinoma. World J Gastroenterol. 2012 October 21; 18(39): 5616–5621. Published online 2012 October 21. doi: 10.3748/wjg.v18.i39.5616.

    9. Zhang LJ, Cai L, Li Z, Wang WP, Guo K, Shao JY, Wang JY, Yu H, Rong TH. Relationship between epidermal gowth factor receptor gene mutation and gene copy number in Chinese patients with non-small cell lung cancer. Chin J Cancer. 2012 October; 31(10): 491–499

    10. Guo K, Cai L, Zhang Y, Zhu JF, Rong TH, Lin P, Hao CL, Wang WP, Li Z, Zhang LJ. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chin J Cancer. 2012 Aug;31(8):399-408. doi: 10.5732/cjc.011.10406. Epub 2012 May 8.

    11. Zheng YZ, Dai SQ, Shan HB, Gao XY, Zhang LJ, Cao X, Zhu JF, Wang JY Managing esophageal leaks by endoscopic transluminal drainage in esophageal cancer patients with superior mediastinal sepsis after esophagectomy. Chin J Cancer. . 2012 Oct 11. 

    12.  Zhang LJ, Cai L, Li Z, Wang WP, Guo K, Shao JY, Wang JY, Yu H, Rong TH.Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer. Chin J Cancer. 2012 Oct;31(10):491-9

    13. Guo K, Cai L, Zhang Y, Zhu JF, Rong TH, Lin P, Hao CL, Wang WP, Li Z, Zhang LJ. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chin J Cancer, 2012 Aug;31(8):399-408.

    14. Jianfei Zhu, Ling Cai, Haoxian Yang, Yinsheng Wen,Junye Wang, Tiehua Rong, Lanjun Zhang. Plasma fibrinogen levels are associated with epidermal growth factor receptor gene mutation in Chinese patients with non-small cell lung cancer. The Chinese-German Journal of Clinical Oncology. 2013, May 12:203-209.

    15. Zhang LJ, Wang WP, Li WY, et al. A new alternative for bony chest wall reconstruction using biomaterial artificial ribs and pleura: animal experiment and clinical application. Eur J Cardiothorac Surg. 2010, OCT; 40(4):939-947.

    16. Dai Y, Long H, Lin P, Fu JH, Zhang LJ, Zhu ZH, Zhang X, Rong TH, Su XD. Impact of the number of resected and involved lymph nodes on the outcome in patients with stage II non-small cell lung cancer. Zhonghua Zhong liu Za Zhi. 2010 jun; 32(6):436-440.

    17. Liu WL, Guo XZ, Zhang LJ, Wang JY, Zhang G, Guan S, Chen YM, Kong QL, Xu LH, Liu MZ, Song LB, Zeng MS. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC cancer. 2010 Sep; 10:467.

    18. Dai Y, Su XD, Long H, Lin P, Fu JH, Zhang LJ, Wang X, Wen ZS, Zhu ZH, Zhang X, Rong TH. Survival analysis of 220 patients with completely resected stage II non-small cell lung cancer. Chin J Cancer. 2010 May; 29(5):538-544.

    19. Xie MR, Zhang X, Lin P, Lin YB, Rong TH, Zhang LJ, Wen ZS, Li XD. Short and lon-term outcomes of neoadjuvant chemotherapy for local advanced esophageal carcinoma. Zhonghua Yi Xue Za Zhi. 2009 Nov; 89(41):2906-2909.

    20. He LR, Zhao HY, Li BK, Zhang LJ, Liu MZ, Kung HF, Bian XW, Zeng YX, Xie D. Overexpression of AIB1 negatively affects survival of surgical resected non-small cell lung cancer patients. Ann Oncol. 2010 Aug; 21(8): 1675-1681.

    21. Yu H, Zhang SY, Wang X, Xie ZM, Wang JY, Li Y, Xie X, Zhou JL, Zhang LJ, Fu JH. Evaluation of scalene lymph node or contralateral mediastinum biopsy during mediastinoscopy for non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2009 Oct; 31(10):780-782.

    22. He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, Chen YC, Zhang LJ, Guan XY, Zeng YX, Kung HF, Xie D. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010 Jul 1; 127(1):138-147.

    23. Zhang DK, Su XD, Lin P, Long H, Fu JH, Zhang LJ, Ma GW, Rong TH. Clinical analysis of 22 cases of esophageal adenosquamous carcinoma. Zhonghua Zhong Liu Za Zhi. 2009 Apr; 31(4):302-304.

    24. Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu JH, Zhang LJ, Su XD, Wu QL, Ling P, Chen M, Xie ZM, Hu Y, Rong TH, Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small cell lung cancer. J Clin Oncol. 2009 Mar 1; 27(7): 1091-1099.

    25. Zhang DK, Su XD, Long H, Lin P, Fu JH, Zhang LJ, Ma GW, Zhu ZH, Dai Y, Rong TH. Surgical treatment and prognosis in patients with squamous cell carcinoma of the thoracic esophagus. Zhonghua Wai Ke Za Zhi. 2008 Sep; 46(17):1333-1336.

    26. Su XD, Long H, Wang X, Fu JH, He JH, Lin P, Zhang LJ, Ma GW. Impact of visceral pleural invasion on the prognosis of stage Ib non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2008 May; 30(5):368-371.

    27. Su XD, Wang X, Rong TH, Long H, Fu JH, Lin P, Zhang LJ, Wang SY, Wen ZS, Ma GW. Prognostic effect of mediastinal lymph node dissection in patients with stage I non-small cell lung cancer. Zhonghua Wai Ke Za Zhi. 2007 Nov 15; 45(22):1543-1545.

    28. Deng YJ, Rong TH, Zhang LJ, Su XD, Lin ZC, Situ DR. Influence of unexpected simultaneous splenectomy on postoperative complications and prognosis of patients undergoing radical esophagectomy for esophageal carcinoma. Ai Zheng. 2007 Sep; 26(9): 983-986.

    29. Li BJ, Wang JY, Huang XP, Zhang LJ, Long H, Yang MT, Rong TH. Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient. Zhonghua Zhong Liu Za Zhi. 2006 Oct; 28(10):766-769.

    30. Lin ZC, Long H, Rong TH, Yang MT, Huang ZF, Lin P, Zhang LJ, Li XD. Surgical treatment efficacy of bronchioloalveolar carcinoma: a retrospective analysis of 130 patients. Ai Zheng. 2006 Sep: 25(9):1123-1126.

    31. Zhang LJ, Rong TH, Xu GL, Su XD, Zhi FC, Guo XM, Zhang PY. Experimental study of preventing postoperative stenosis by modifying artificial esophagus in dogs. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006 Jun; 28(3):325-328.

    32. Zhang LJ, Rong TH, Wu QL, Su XD, Long H, Zhao JM, Zhang PY, Li XD. Histological regeneration process of “neo-esophagus”. Ai Zheng. 2006 Jun; 25(6): 689-695.

    33. Zhang PY, Li BJ, Su XD, Wen ZS, Zhao JM, Zhang LJ, Long H, Rong TH. In vitro killing effects of STI571 on esophageal carcinoma cell lines CE-48T and CE-81T. Ai Zheng. 2006 Apr; 25(4): 456-60.

    34. Huang XP,Rong TH, Wang JY, Tang YQ, Li BJ, Xu DR, Zhao MQ, Zhang LJ, Fang Y, Su XD, Liang QW. Negative implication of C-MYC as an amplification target in esophageal cancer. Cancer Genet Cytogenet. 2006 Feb; 165(1): 20-24.


    Last Updated on: February 2016

    Lin Peng
    Title Deputy Director of Department of Thoracic Surgery, Chief Physician, and advisor of master's degree student
    Profile

    Dr. Lin specializes in thoracic surgical treatment, especially surgical treatment and combination therapy of complex lung cancer case, esophagus cancer and malignant pleural mesothelioma, and studies on improvement of staging of esophagus cancer and standardization of lymph node dissection.

    Work experience
    1987-present: Work at Thoracic Surgery of Sun Yat-sen University Cancer Center

    2003: Served as Director of the third district of Thoracic Surgery of Sun Yat-sen University Cancer Center, and advisor of master's degree student

    2006: Served as Deputy Director of Department of Thoracic Surgery of Sun Yat-sen University Cancer Center

    Email
    Phone
    Research Interest(s)
    Surgical treatment and combination therapy of esophagus cancer and lung cancer, improvement of staging of esophagus cancer and standardization of lymph node dissection
    Education

    1981-1987: Undergraduate, Department of Medicine, former Zhongshan Medicine School

    1995-2000: Part-time doctoral student, Doctoral Degree in Oncology, former Sun Yat-sen University of Medical Sciences

    2002: Studied clinical thoracic surgery at University of Texas MD Anderson Cancer for half a year

    Publications
    Long Hao
    Title Professor, Chief Physician, Advisor of Master's Degree Student, Director of Lung Cancer Research Center of Sun Yat-sen University, Deputy Director of Department of Thoracic Surgery
    Profile

    Prof. Long Hao specializes in minimally invasive thoracic surgery, thoracoscopy, chest wall reconstruction, combination therapy of lung cancer, esophagus cancer and breast cancer, especially surgical treatment of pulmonary metastasis, having intense studies on both clinical and research work.

    Work experience
    1984-1990 Hunan Cancer Hospital

    1990-present Sun Yat-sen University Cancer Center

    2010-present Director of Lung Cancer Research Center, Sun Yat-sen University

    Email
    Phone
    Research Interest(s)

    Minimally invasive thoracic surgery and repair and construction

    Education

    1984 Graduated from Department of Medicine, former Sun Yat-sen University of Medical Sciences

    2000-2001 Served as Clinic Fellow at Austin Hospital of University of Melbourne

    2002 Specialized in minimally invasive thoracic surgery at Prince of Wales Hospital, the Chinese University of Hong Kong

    2004 Studied lung transplantation at Toronto General Hospital

    Publications
    Rong Tiehua
    Title Professor, Doctoral Advisor, Chief specialist of esophagus cancer and lung cancer in Sun Yat-sen University Cancer Center
    Profile
    Prof. Rong Tiehua has been engaged in surgical treatment of esophagus cancer, lung cancer, breast cancer, mediastinal tumor and giant chest wall tumor for 30 years.

    Last Updated on: September 2014

    Email
    Phone
    Research Interest(s)
    1. Improvement of surgical treatment of esophagus cancer

    2. Clinical research on rules of lymph node metastasis of esophagus cancer

    3. Molecular biological study on lymph node metastasis of esophagus cancer

    4. Design optimization of individualized treatment of esophagus cancer; all of his researches have gained periodic achievements

    Education
    Publications
    Fu Jian-Hua
    Title Professor and Director of Guangdong Esophageal Cancer Institute
    Profile

    Dr. Jian-Hua Fu is the professor of thoracic cancers and director of Guangdong Esophageal Cancer Institute. Dr. Fu obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 1987 and 2002, respectively, He is one of the most skilled thoracic surgeons in China, especially in the field of minimally invasive esophagectomy. He is the leading specialist in the diagnosis and treatment of Chinese esophageal cancers. He is currently a member of the standing committee of Chinese Anti-Cancer Association (CACA) of Esophageal Cancer, a member of the standing executive committee of Chinese Society of Clinical Oncology (CSCO), a member of Chinese Society for Thoracic and Cardiovascular Surgery (CSTCS), vice-president of Chinese Association of Thoracic Surgeons, president of Guangdong Anti-Cancer Association of Esophageal Cancer, vice-president of Guangdong Medical Association of Oncology. He was rewarded the second class of Guangdong Award for the Scientific and Technological Advancement in 2006, and the third class in 1999, respectively. He has published more than 40 papers in world famous journals, such as Ann Surg, Ann Oncol, J Thorac Oncol, Br J Surg, Br J Cancer, and et al, and over 100 papers in Chinese core journals as the corresponding author or first author.

     
    Email fujh@sysucc.org.cn
    Phone 86-20-87343628
    Research Interest(s)

    My primary interest is the comprehensive treatment of esophageal squamous cell carcinomas (ESCCs), and a series of clinical and translational studies were conducted on it. A randomized controlled multi-centre Phase-III trial (Trial registration: NCT01216527) to compare two treatment strategies for ESCC patients at advanced stage, neo-adjuvant chemoradiotherapy (CRT) plus surgery and surgery alone, has completed patient enrollment in 2014. A preliminary analysis of the clinical trial performed in 2013 showed that neo-adjuvant CRT significantly improved R0 resection rate. The cohort of patients receiving neo-adjuvant CRT followed by surgery exhibited better overall and disease-free survival than that of surgery alone. A new Phase-III trial comparing two neo-adjuvant CRT regimens, docetaxol plus cisplatin and vinorelbine plus cisplatin was started in July, 2015, which intends to further optimize ESCC neo-adjuvant CRT strategy. Along with the clinical trial, mRNA and miRNA microarray and high-throughput sequencing studies of pre-treatment tumour biopsies are conducted in ESCC patients who received neo-adjuvant CRT so as to identify molecular markers for patients’ CRT response and survival prediction. Prediction models based on mRNA and miRNA expression were built up, which exhibited good sensitivity and specificity in classifying responders and non-responders after neo-adjuvant CRT.

    Education

    Bechalor in Medicine, Sun Yat-sen University (1987)

    PhD. Sun Yat-sen University (2002)

    EMBA, Sun Yat-sen University (2005)

     

    Publications

    Publication from the past 5 years:                                                                              

    1. Huang QY, Luo KJ, Chen C, Wang G, Jin JT, Kong M, Li BF, Liu QW, Li JH, Rong TH, Chen HQ, Zhang LJ, Chen YP, Zhu CC, Zheng B, Wen J, Zheng YZ, Tan ZH, Xie XY, Yang H, Fu JH(corresponding author), Identification and Validation of Lymphovascular Invasion as a Prognostic and Staging Factor in Node-Negative Esophageal Squamous Cell Carcinoma, J Thorac Oncol, 2016 Jan 11. [Epub ahead of print]                                                             

    2. Zhang SS, Xie X, Wen J, Luo KJ, Liu QW, Yang H, Hu Y, Fu JH(corresponding author), TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma, Diagn Pathol, 2016, 11(1): 14.                               

    3. Wen J, Liu QW, Luo KJ, Ling YH, Xie XY, Yang H, Hu Y, Fu JH(corresponding author), MIIP expression predicts outcomes of surgically resected esophageal squamous cell carcinomas, Tumour Biol. 2016 Jan 29. [Epub ahead of print]    

    4. Wen J, Luo KJ, Liu H, Liu SL, Lin GR, Hu Y, Zhang X, Wang G, Chen YP, Chen ZJ, Li Y, Lin T, Xie XY, Liu MZ, Wang HY, Yang H, Fu JH(corresponding author), MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy, Ann Surg, 2015 Oct 1. [Epub ahead of print]                                                                                               

    5. Chen JY, Wen J, Zheng YZ, Yang H, Luo KJ, Liu QW, Hu RG, Tan ZH, Huang QY, Fu JH(corresponding author), Prognostic significance of SLC9A9 in patients with resectable esophageal squamous cell carcinoma, Tumour Biol, 2015, 36(9): 6797-6803.                                                                                                         

    6. Zheng YZ, Zhao W, Hu Y, Ding-Lin XX, Wen J, Yang H, Liu QW, Luo KJ, Huang QY, Chen JY, Fu JH(corresponding author), Aggressive surgical resection does not improve survival in operable esophageal squamous cell carcinoma with N2-3 status, World J Gastroenterol, 2015, 21(28): 8644-8652.                                                           

    7. Chen JY, Yang H, Wen J, Luo KJ, Liu QW, Huang YJ, Zheng YZ, Tan ZH, Huang QY, Fu JH(corresponding author), NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/beta-catenin pathway and Bcl-2 expression, Oncotarget, 2015, 6(14): 12405-12420.                                                         8. Zheng YZ, Cao X, Wen J, Yang H, Luo KJ, Liu QW, Huang QY, Chen JY, Fu JH(corresponding author), Smoking affects treatment outcome in patients with resected esophageal squamous cell carcinoma who received chemotherapy, PLos One, 2015, 10(4): e0123246-e0123246.    

    9. Yang F, Zhang SS, Yang H, Luo KJ, Wen J, Hu Y, Hu RG, Huang QY, Chen JY, Fu JH(corresponding author), Prognostic significance of gamma-glutamyltransferase in patients with resectable esophageal squamous cell carcinoma, Dis Esophagus, 2015, 28(5): 496-504.     

    10. Huang QY, Su XD, Bella AE, Luo KJ, Jin JT, Zhang SS, Luo GY, Rong TH, Fu JH(corresponding author), Clinicopathological features and outcome of gastric metastases from primary lung cancer: A case report and systematic review. Oncol Lett, 2015, 9(3): 1373-1379.    

    11. Huang QY, Zhong JD, Yang TZ, Li JH, Luo KJ, Zheng YZ, Yang H, Fu JH(corresponding author), Impacts of anastomotic complications on the health-related quality of life after esophagectomy, J Surg Oncol, 2015, 111(4): 365-370.   

    12. Ma GW, Zhang X, Ma QL, Rong TH, Long H, Lin P, Fu JH(co-corresponding author), Zhang LJ, A novel multivariate scoring system for determining the prognosis of lymph node-negative esophageal squamous cell carcinoma following surgical therapy: An observational study, Eur J Surg Oncol. 2015, 41(4): 541-547.    

    13. Zhu YH, Zhang BZ, Li MQ, Huang PZ, Sun J, Fu JH(co-corresponding author), Guan XY, Prognostic significance of FAM3C in esophageal squamous cell carcinoma. Diagn Pathol. 2015, 10: 192. 

    14. Yang F, Zhang S, Yang H, Luo K, Wen J, Hu Y, Hu R, Huang Q, Chen J, Fu JH(corresponding author). Prognostic significance of gamma-glutamyltransferase in patients with resectable esophageal squamous cell carcinoma. Dis Esophagus. 2015, 28(5): 496-504.      

    15. Wen J, Yang H, Liu MZ, Luo KJ, Liu H, Hu Y, Zhang X, Lai RC, Lin T, Wang HY, Fu JH (corresponding author). Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy. Ann Oncol. 2014, 25(9): 1769-74.          

    16. Bella AE, Zhang YR, Fan W, Luo KJ, Rong TH, Lin P, Yang H, Fu JH(corresponding author). Maximum standardized uptake value on PET/CT in preoperative assessment of lymph node metastasis from thoracic esophageal squamous cell carcinoma. Chin J Cancer, 2014, 33(4): 211-217.   

    17. Liu QW, Ma GW, Yang HX, Wen J, Li M, Yang H, Luo KJ, Hu Y, Fu JH(corresponding author), Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma-like carcinoma of the lung, Thorac Cancer, 2014, 5(1): 63-67.    

    18. Huang QY, Luo KJ, Yang H, Wen J, Zhang SS, Li JH, Bella AE, Liu QW, Yang F, Zheng YZ, Hu RG, Chen JY, Fu JH(corresponding author), Impact of alcohol consumption on survival in patients with esophageal carcinoma: a large cohort with long-term follow-up, Cancer Sci, 2014, 105(12): 1638-1646.                                                             19. Zhang SS, Yang H, Xie X, Luo KJ, Wen J, Bella AE, Hu Y, Yang F, Fu JH(corresponding author), Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies, Dis Esophagus, 2014, 27(6): 574-584.    

    20. Xie X, Zhang SS, Wen J, Yang H, Luo KJ, Yang F, Hu Y, Fu JH(corresponding author), Protein kinase D1 mRNA level may predict cancer-specific survival in heavy smokers with esophageal squamous cell cancers, Dis Esophagus, 2014, 27(2): 188-195.                

    21. Zhang SS, Yang H, Luo KJ, Huang QY, Chen JY, Yang F, Cai XL, Xie X, Liu QW, Bella AE, Hu RG, Wen J, Hu Y, Fu JH(corresponding author).The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. Br J Cancer. 2013;109(11):2894-2903.                                                            22.Yang HX, Feng W, Wei JC, Zeng TS, Li ZD, Zhang LJ, Lin P, Luo RZ, He JH, Fu JH (corresponding author). Support vector machine-based nomogram predicts postoperative distant metastasis for patients with oesophageal squamous cell carcinoma. Br J Cancer. 2013;109(5):1109-1116.  

    23. Zhang SS, Wen J, Yang F, Cai XL, Yang H, Luo KJ, Liu QW, Hu RG, Xie X, Huang QY, Chen JY, Fu JH (co-corresponding author), Hu Y. High expression of transient potential receptor C6 correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Med Oncol. 2013;30(3):607.  

    24. Xie X, Zhang SS, Wen J, Yang H, Luo KJ, Yang F, Hu Y, Fu JH (corresponding author). Prognostic value of HOXB7 mRNA expression in human oesophageal squamous cell cancer. Biomarkers. 2013 18(4):297-303.    

    25. Zhang SS, Huang QY, Yang H, Xie X, Luo KJ, Wen J, Cai XL, Yang F, Hu Y, Fu JH (corresponding author). Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis. Ann Surg Oncol. 2013;20(7):2419-2427.  

    26. Wen J, Luo KJ, Hu Y, Yang H, Fu JH(corresponding author). Metastatic lymph node CHIP expression is a potential prognostic marker for resected esophageal squamous cell carcinoma patients. Ann Surg Oncol. 2013;20(5):1668-1675.

    27. Wen J, Hu Y, Luo KJ, Yang H, Zhang SS, Fu JH (corresponding author). Positive transforming growth factor-β activated kinase-1 expression has an unfavorable impact on survival in T3N1-3M0 esophageal squamous cell carcinomas. Ann Thorac Surg. 2013;95(1):285-290.      

    28. Li XH, Hu Y, Rong TH, Li XD, Su XD, Yang H, Bella AE, Fu JH (corresponding author). Medical thoracoscopy and gastroscopy for the treatment of intrathoracic anastomotic leakage following esophagectomy. Oncol Lett. 2013;5(1):198-200.  

    29. Tang J, Deng R, Luo RZ, Shen GP, Cai MY, Du ZM, Jiang S, Yang MT, Fu JH (co-corresponding author), Zhu XF. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2012;134(2):549-560.                                                                               30. Yang HX, Hou X, Liu QW, Zhang LJ, Liu JG, Lin P, Fu JH (corresponding author). Tumor Location Does Not Impact Long-Term Survival in Patients With Operable Thoracic Esophageal Squamous Cell Carcinoma in China. Ann Thorac Surg. 2012;93(6):1861-1866.    

    31. Liu J, Xie X, Zhou C, Peng S, Rao D, Fu J (corresponding author). Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg. 2012;41(3):e7-e11.        

    32. Liu J, Hu Y, Xie X, Fu J (corresponding author). Subcarinal node metastasis in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2012;93(2):423-427.                                                                                 

    33. Liu J, Hu Y, Cui C, Li Y, Lin X, Fu J (corresponding author). Removable, Fully Covered, Self-expandable Metal Stents for the Treatment of Refractory Benign Esophagogastric Anastomotic Strictures. Dysphagia. 2012;27(2):260-264.                       

    34. Lin X, Wang J, Han F, Fu J (corresponding author), Li A. Analysis of eighty-one cases with breast lesions using automated breast volume scanner and comparison with handheld ultrasound. Eur J Radiol. 2012;81(5):873-878.  34. Luo KJ, Hu Y, Wen J, Fu JH (corresponding author). CyclinD1, p53, E-cadherin, and VEGF discordant expression in paired regional metastatic lymph nodes of esophageal squamous cell carcinoma: A tissue array analysis. J Surg Oncol. 2011;104(3):236-243.                                                                                     

    35. Yang HX, Wei JC, Xu Y, Liu JG, Lin P, Rong TH, Fu JH (corresponding author). Modification of nodal categories in the seventh american joint committee on cancer staging system for esophageal squamous cell carcinoma in Chinese patients. Ann Thorac Surg. 2011;92(1):216-224.                                                                                                                              

    36. Tang J, Xie XM, Wang X, Xie ZM, He JH, Wu YP, Fan W, Fu JH (co-corresponding author), Yang MT. Radiocolloid in Combination with Methylene Dye Localization, Rather Than Wire Localization, is a Preferred Procedure for Excisional Biopsy of Nonpalpable Breast Lesions. Ann Surg Oncol. 2011;18(1):109-113.  

    37. Liu QW, Fu JH (corresponding author), Luo KJ, Yang HX, Wang JY, Hu Y, Yang H, Bella E. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Dis Esophagus. 2011, 24(5):374-380.

     
    Last Updated on: March 2016

    Si-Yu Wang
    Title Professor
    Profile

    Professional experience
    2008-present: Professor, Cancer Center, Sun Yat-sen University, China;

    2000-2008 : Associate Professor, Cancer Center, Sun Yat-sen University, China;

    1988-2000: Attending Doctor, Cancer Center, Sun Yat-Sen University of Medical Sciences, China

    Professional memberships/activities
    member of American Society of Clinical Oncology

    member of International Associated Study of Lung Cancer

    committee member--Chinese Society of Lung Cancer

    committee member--Chinese Society of Clinical Oncology

    committee member of editorial board--Chinese Journal of Lung Cancer

    committee member of editorial board--The Journal of Evidence-Based Medicine

    Honors and awards
    1. First Grade Award of Guangdong Provincial Science and Technology Award, 2009

    2. Second Grade Award of Guangdong Provincial Science and Technology Award, 2001

    3. Excellent research paper of the 7th annual meeting of Chinese society of clinical oncology

    4. Excellent research paper of science fund of Chinese society of clinical oncology, 2006

    5. Travel Award of the 4th Asia Pacific Lung Cancer Group, 2010

    Email wsysums@163.net
    Phone +86 20 87343439
    Research Interest(s)

    Editor in Chief : Chinese Journal of Clinical Oncology education edition, Sun Yat-sen University Press,2002.Associate Editor: Lung cancer——Principles and Practice of Multidisciplinary Synthetic Therapy,2000,People’s Medical Publishing House.

    Editorial board member: 1 Horizons in Cancer Research,2011,Nova Science Publishers,Inc.New York.2 Chinese Journal of Clinical Oncology education edition,China Ocean University Press,2005.3 Chinese Journal of Clinical Oncology education edition,Peking Union Medical College Press,2006.

    Education 1982.9.-1988.7: Medical Student of Sun Yet-sen University of Medical Science
    Publications

    Main papers:

    1. Ou W, Sun HB, Ye X, Zhang BB, Yang H, Fang Q, Li P, Wang SY (*). Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer. J Thorac Oncol. 2010 Jul;5(7):1033-41.

    2. Sun HB, Wang SY (*), Ou W, Zhang BB, Yang H, Fang Q. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer. Lung Cancer. 2010 Jun;68(3):403-8.

    3. Wang SY (*), Ye X, Ou W, Lin YB, Zhang BB, Yang H. Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer. 2009 May;64(2):238-43.

    4. Hai-bo Sun, Yan Zheng, Si-yu Wang (*), Wei Ou, Qin Fang. Association Between Hormone Receptor Expression and Epidermal Growth Factor Receptor Mutation in Patients Operated on for Non-small Cell Lung Cancer. Annals of Thoracic Surgery: 2011,91:1562-1567.

    5 Liang Zhang ,Wei Ou ,Qianwen Liu ,Ning Li ,Li Liu Siyu Wang (*) Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamousnon-small cell lung cancer. Thoracic Cancer 5 (2014) 50-55

    6. Qin Fang ,Hu aYang ,Wei Ou ,Xiong Ye ,Bin-bin Zhang ,Hai-bo Sun ,Liang Zhang ,Xun Cao , Si-yu Wang (*) Discordance of epidermal growth factor receptor mutations between primary tumors and corresponding mediastinal nodal metastases in patients operated on for stage N2 non-small cell lung cancer. Thoracic Cancer3(2012)313-319

    7. Ning Li, MD ,Wei Ou, MD ,XiongYe, MD ,Hai-Bo Sun, MD ,Liang Zhang, MD ,Qin Fang, MD ,Song-Liang Zhang, MD,Bao-Xiao Wang ,and Si-Yu Wang, MD (*) Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II Study Ann Surg Oncol (2014)21:2091-2096

    8 NingLi,MD ;Wei Ou, MD ;Hua Yang, MD ;Qian-Wen Liu,MD ; Song-Liang Zhang, MD ;Bao-Xiao Wang, MD ;and Si-Yu Wang, MD (*) A Randomized Phase 2 Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in the Treatment of Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma. Cancer,2014,May

    9. Ning Li ,Lu Yang ,Wei Ou ,Liang Zhang ,Song-liang Zhang ,Si-yu Wang (*) Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer. PLOS ONE 2014 July Volume 9 Issue 7 e102777

    10. Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 2002 Apr;36(1):1-6.


    Last Updated on: August 2014

    Wang Xin
    Title Chief physician and advisor of master's degree student
    Profile

    Prof. Wang specializes in diagnosis, staging, surgical treatment and multimodality treatment of non-small cell lung cancer, multimodality treatment of N2 non-small cell lung cancer, surgical treatment of lung cancer and chronic obstructive lung disease, pulmonary sulcus tumor, and tracheal/bronchial tumor, diagnosis, staging, surgical treatment and multimodality treatment of esophagus cancer, en bloc esophagectomy, three-field lymph node dissection, and early diagnosis, surgical treatment and multimodality treatment of breast cancer.
    1986-present: Work at Thoracic Surgery of Sun Yat-sen University Cancer Center

    Email
    Phone
    Research Interest(s)
    Education
    1980-1986: Studied at Department of Medicine, former Sun Yat-sen University of Medical Sciences

    1998-2000: Studied as a visiting scholar at Strang Cancer Prevention Institute, former New York Hospital-Cornell Medical Center, Memorial Sloan-Kettering Cancer Center and Barnes-Jewish Hospital, Washington University School of Medicine

    2004-2007: Studied at School of Public Health, Sun Yat-sen University as a part-time master's student (Master of Public Health)

    Publications
    Wang Junye
    Title Chief physician, Professor and advisor of master's degree student
    Profile

    Dr. Wang has been engaged in clinical work, teaching and scientific research for 17 years, gaining abundant experiences and laying solid theoretical foundation. He achieves within thoracic diagnosis, surgical treatment and combination therapy, having especially abundant clinical experiences with aged patients.

    He is proficient in thoracic surgical techniques, especially the application of minimally invasive thoracic surgical techniques such as mediastinoscope and thoracoscope in thoracic diagnosis and treatment. Besides, he is proficient in conducting thoracoscopic esophagectomy for esophageal cancer + thoracic lymph node dissection, thoracoscopic lobectomy + mediastinoscopy lymph node dissection, thoracoscopic surgery for mediastinal tumor, thoracoscopic cautery division of pleural adhesion and wedge resection of lung, etc. He is able to use mediastinoscope in diagnosis and staging of lung cancer, and diagnosis of mediastinal lymph node enlargement.

    07/2003-present: Work at Thoracic Surgery of Sun Yat-sen University Cancer Center, engaging himself in medical treatment, teaching and scientific research

    2006: Associate professor, Sun Yat-sen University Cancer Center

    Email
    Phone
    Research Interest(s)

    Esophagus cancer
    1. Devoted to studies of tumor marker in the diagnosis, especially early diagnosis of esophagus cancer. Studies of serological proteome analysis for screening of specific marker of esophageal squamous-cell carcinoma were conducted

    2. Devoted to studies of development of early diagnosis, especially tool of screening for esophagus cancer. In 2008, resettable esophageal capsule endoscopy was granted the patten for utility model with patten No. of ZL200720047363.6

    3. Studies of nutrition support and nutrition therapy before and after esophagus cancer surgery and etc.

    Lung cancer
    1. Studies of screening of micromolecule polypeptide and ligand by using phage display peptide library

    2. Studies of application of screened polypeptide in lung cancer

    Education
    1987-1992: Completed undergraduate program at Department of Medical Science, College of Medical Science, Qingdao University and was conferred upon the degree of Bachelor Medicine; Started medical treatment, teaching and scientific research of thoracic surgery after graduation

    2000-2003: Completed master's program of oncology at Sun Yat-sen University of Medical Sciences and was conferred upon the degree of Master of Oncology of Sun Yat-sen University

    2009: Conferred upon Doctor of Oncology of Sun Yat-sen University

    Publications
    Wen Zhesheng
    Title Chief physician, Professor and advisor of master's degree student
    Profile

    Dr. Wen has many years of experiences in thoracic surgical treatment, teaching and scientific searches, obtaining profound achievements in comprehensive clinical management and surgical treatment of lung cancer, esophagus cancer and breast cancer, especially early screening and diagnosis of lung cancer.

    Work experience
    07/1987-08/1991: Served as a surgeon at Department of Surgery of the Affiliated Hospital of Jiangxi Jiujiang Medical School

    07/1994-08/2000: Served as an attending physician at Department of Surgery of Guangzhou Chest Hospital

    2003-present: Work at Sun Yat-sen University Cancer Center

    Email
    Phone
    Research Interest(s)
    Education 09/1982-07/1987: Studied at School of Clinical Department, former Jiangxi Medical College

    09/1991-06/1994: Studied at Surgery of Sun Yat-sen University of Medical Sciences for a master's degree

    09/2000-06/2003: Studied Oncology at Sun Yat-sen University for a doctoral degree

    10/2000-08/2002: Studied on analgesic-antitumor peptide in Japan

    Publications
    Yu Hui
    Title Associate professor and associate chief physician
    Profile
    Prof. Yu specializes in diagnosis of thoracic tumor, surgical treatment and combination therapy featuring chemotherapy, especially diagnosis and standardized surgical treatment of lung cancer, esophagus cancer, breast cancer and mediastinal tumor. He has abundant clinical experiences in evaluation of perioperative risks of thoracic surgery and prevention, diagnosis and treatment of complications. He has been working in Thoracic Surgery at Sun Yat-sen University Cancer Center since 1991, focusing both on clinical work and teaching for more than 20 years.
    Email
    Phone
    Research Interest(s)
    Education
    1986-1991: Completed the six-year undergraduate program (English teaching class) of Clinical Medicine at Department of Medicine, former Sun Yat-sen University of Medical Sciences

    08/1993-07/1994: Received systematic training and studied at different specialties of Department of Surgery of the First Affiliated Hospital, Sun Yat-sen University

    08/1994-05/1995: Went to America for further study

    2001: Obtained Master of Clinical Medicine (Oncology) of former Sun Yat-sen University of Medical Sciences

    Publications
    Zhu Zhihua
    Title Associate Professor
    Profile
    Prof. Zhu has mastered radical mastectomy, modified radical mastectomy, breast-conserving surgery, thoracoscopic lobectomy, radical resections for lung cancer, and etc. He is also experienced in perioperative management and handling various types of complication, especially combination therapy of tumor. He has been working at Sun Yat-sen University Cancer Center since 2005, focusing on clinical work, and currently serves as associate professor of Thoracic Surgery.
    Email
    Phone
    Research Interest(s)
    Education
    1997: Completed undergraduate program from Department of Medicine of Wannan Medical College

    1999-2005 Studied at Sun Yat-sen University Cancer Center and was conferred upon the degree of Master of Oncology and Doctor of Oncology

    Publications

    Sun P, Zhang F, Chen C, An X, Li YH, Wang FH, Zhu ZH (2013) Comparison of the prognostic values of various nutritional parameters in patients with esophageal squamous cell carcinoma from Southern China. J Thorac Dis 5:484-91通讯

    Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379:823-32

    Xia Q, Zhu Z, Wang J, Situ D, Zhou N, Jang W (2012) Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer. Tumour Biol 33:1719-25通讯

    Wang J, Ma Y, Zhu ZH, Situ DR, Hu Y, Rong TH (2012) Expression and prognostic relevance of tumor carcinoembryonic antigen in stage IB non-small cell lung cancer. J Thorac Dis 4:490-6通讯

    Liu AN;Zhu ZH;Chang SJ;Hang XS (2012) Twist expression associated with the epithelial-mesenchymal transition in gastric cancer.Mol Cell Biochem 367(1-2):195-203共同第一

    Hao C, Wei S, Tong Z, Li S, Shi Y, Wang X, Zhu ZH(2012)The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro.Tumour Biol 33(4):1159-67

    Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL, Lee M, Liu ZW, Chen J, Zhang JX, Zhang HZ, He JH, Chen FL, Zhu XD, Huang MY, Liao DZ, Fu J, Shao Q, Cai MB, Du ZM, Yan LX, Hu CF, Ng HK, Wee JT, Qian CN, Liu Q, Ernberg I, Ye W, Adami HO, Chan AT, Zeng YX, Shao JY (2011) Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. J Clin Oncol 29:4516-25共同第一

    Situ D, Wang J, Ma Y, Zhu ZH, Hu Y, Long H, Rong T (2011) Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol 28 Suppl 1:S596-604通讯

    Hu Y;Ma Y;Wang J;Zhu ZH(2011)Early enteral infusion of traditional Chinese medicine preparation can effectively promote the recovery of gastrointestinal function after esophageal cancer surgery.J Thorac Dis 3:249-54通讯

    Sun BY, Zhu ZH, Li J, Linghu B (2011) Combined feature selection and cancer prognosis using support vector machine regression. IEEE/ACM Trans Comput Biol Bioinform 8:1671-7

    Situ D, Long H, Lin P, Zhu ZH, Wang J, Zhang X, Xie Z, Rong T (2010a) Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol 136:1213-9通讯

    Situ DR, Hu Y, Zhu ZH, Wang J, Long H, Rong TH (2010b) Prognostic relevance of beta-catenin expression in T2-3N0M0 esophageal squamous cell carcinoma. World J Gastroenterol 16:5195-202通讯

    Dai Y, Long H, Lin P, Fu JH, Zhang LJ, Zhu ZH, Zhang X, Rong TH, Su XD (2010) [Impact of the number of resected and involved lymph nodes on the outcome in patients with stage II non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 32:436-40
      
    Hu Y, Zheng B, Fu JH, Rong TH, Yang H, Luo KJ, Li YF, Zhu ZH (2010) [Clinical evaluation of endoscopic ultrasonography and CT in the prediction of the resectability of esophageal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi 13:205-9

    Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu JH, Zhang LJ, Su XD, Wu QL, Ling P, Chen M, Xie ZM, Hu Y, Rong TH (2009) Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol 27:1091-9

    Zhang X, Lin P, Zhu ZH, Long H, Wen J, Yang H, Zhang X, Wang DF, Fu JH, Fang Y, Rong TH (2009) Expression profiles of early esophageal squamous cell carcinoma by cDNA microarray. Cancer Genet Cytogenet 194:23-9

    Zhang X, Zhu ZH, Lin P, Yang H, Fu JH, Zhang LJ, Long H, Wen J, Huang XP, Fang Y, Rong TH (2008b) [Analyzing the profile of chromosomal imbalances in esophageal atypical hyperplasia and early stage esophageal squamous cell carcinoma by 250K Snp Array]. Zhonghua Yi Xue Za Zhi 88:2636-41

    Zhang DK, Su XD, Long H, Lin P, Fu JH, Zhang LJ, Ma GW, Zhu ZH, Dai Y, Rong TH (2008a) [Surgical treatment and prognosis in patients with squamous cell carcinoma of thoracic esophagus]. Zhonghua Wai Ke Za Zhi 46:1333-6

    Hu Y, Fu JH, Rong TH, Yang H, Huang WZ, Wang G, Zheng B, Zhu ZH (2008) [Diagnostic value of endoscopic ultrasonography and CT in T, N stage of preoperative esophageal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 11:150-3

    Zhang SY, Wang X, Rong TH, Zheng L, Zeng CG, Xie ZM, Yu H, Zhu ZH (2007) [Evaluation of lymph node metastasis in the contralateral mediastinum or scalene  through mediastinoscopy and para-mediastinal small incision in potentially operable non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 29:629-31

    Zhu ZH, Rong TH, Zeng CG, Wu QL, Ma Y, Huang XP, Li BJ, Zhang PY, Zhao JM, Hu W, Zhang SY, Yu H, Ma GW, Zhang LJ, Wen ZS, Fu JH, Long H (2005a) [Vascular endothelial growth factor expression and microvessel density in stage I-II non-small cell lung cancer and their prognostic significances]. Ai Zheng 24:865-9

    Zhu ZH, Li BJ, Zhang SY, Rong TH, Zeng CG, Yu H, Hu Y, Zhang X, Fu JH, Long H, Lin P, Wang SY, Wang X, Yang MT, Huang ZF (2005b) [Predictive value of detection of sentinel lymph nodes on lymphatic metastasis of non-small cell lung cancer]. Ai Zheng 24:341-4

    Zhang SY, Wang X, Zhu ZH, Zeng CG, Rong TH, Zheng L, Fu JH, Xie ZM, Zhang X, Yu H (2005) [Clinical value of cervical mediastinoscopy in non-small cell lung cancer of stage I]. Ai Zheng 24:349-52

    Li BJ, Zhu ZH, Wang JY, Hou JH, Zhao JM, Zhang PY, Yao GY, Wang X, Long H, Yang MT, Rong TH (2004) [Expression correlation of Ki67 to P53,VEGF,and C-erbB-2 genes in breast cancer and their clinical significances]. Ai Zheng 23:1176-9

    Ma GW, Rong TH, Long H, Fu JH, Lin P, Huang ZF, Zeng CG, Zhang X, Li XD, Zhang LJ, Wen ZS, Wang JY, Zhang PY, Hu Y, Zhu ZH (2004) [Shrinkage of resected specimens of esophageal carcinoma]. Ai Zheng 23:193-5

     
    Ma Guowei
    Title Associate Professor, Associate chief physician and advisor of master's degree student
    Profile

    Prof. Ma is experienced in diagnosis and treatment of thoracic cancer (lung cancer, breast cancer, esophagus cancer, mediastinal tumor, chest wall tumor, and etc.). He is able to conduct the following surgical procedures proficiently:

    1. Lobectomy, pneumonectomy, wedge resection and VATS pleural biopsy and pleurodesis, mediastinoscopy with biopsy and anterior mediastinotomy and VATA lobectomy;

    2. Right transpleural esophagectomy for mid-lower esophagus cancer (cardiac carcinoma), supra-aortic arch and infra-aortic arch esophagogastrostomy, three-incision esophagectomy for mid-lower esophagus cancer, left cervical esophagogastrostomy and VATS esophagectomy for esophageal cancer;

    3. Benign breast disease surgeries (segmental mastectomy, quadrantectomy, simple mastectomy and etc.); He has mastered modified radical mastectomy (Auchinclos and Patey) and standard radical mastectomy (Halsted), as well as breast-conserving surgery and sentinel lymph node biopsy.

    4. Chest wall and mediastinal tumor surgery

    Work experience
    07/1994-11/2000 Sun Yat-sen University Cancer Center, surgeon

    11/2000-12/2003 Sun Yat-sen University Cancer Center, attending physician

    01/2004-08/2004 Toronto General Hospital, Visiting physician (studied thoracic surgery and transplant)

    09/2004-01/2006 Canadian Surgical Technologies & Advanced Robotics (CSTAR), research fellow (studied application of robots in the field of thoracic surgery)

    University of Western Ontario, clinical fellow (thoracic surgery)

    01/2006-12/2007 Sun Yat-sen University Cancer Center, attending physician

    01/2008-present Sun Yat-sen University Cancer Center, associate chief physician

    Email
    Phone
    Research Interest(s)
    Diagnosis and treatment of thoracic cancer (lung cancer, breast cancer, esophagus cancer, mediastinal tumor, chest wall tumor, and etc.)
    Education
    09/1989-07/1994 Bachelor of Medicine in Clinical Medicine, former Sun Yat-sen University of Medical Sciences

    09/1998-07/2001 Master of Medicine in Clinical Medicine, former Sun Yat-sen University of Medical Sciences

    09/2001-12/2003 Doctor of Medicine in Clinical Medicine, Sun Yat-sen University

    09/2004-01/2006 Postdoctoral degree, University of Western Ontario

    Publications
    Hao-Xian Yang
    Title Associate Professor; Attending Surgeon
    Profile
    Dr. Hao-Xian Yang is an associate professor and attending surgeon of thoracic surgery at Sun Yat-sen University Cancer Center. Dr. Yang obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 1999 and 2004, respectively. His postdoctoral training at Sun Yat-sen University Cancer Center and research experience at Memorial Sloan-Kettering Cancer Center in the United States provided him with great opportunities to explore the fields of minimally invasive thoracic surgeries, including the vedio-assisted thoracic surgery (VATS) and robot-assisted thoracic surgery (RATS). He has been doing clinical research work and receiving minimally invasive thoracic surgery training including but not limited to robot-assisted thoracic surgery at Memorial Sloan-Kettering Cancer Center in the United States from January 2014. Dr Hao-Xian Yang is interested in the metastases mechanism and prognosis of lung cancer , esophageal cancer, and minimally invasive thoracic surgery in which leads to more than 20 research publications.
     
    Last Updated on: August 2014
    Email yanghx@sysucc.org.cn
    Phone 86-20-87343258
    Research Interest(s)

    (1) Minimally invasive thoracic surgery, multidisciplinary and individualized therapy of thoracic cancers, including lung cancer, esophageal cancer and mediastinal cancers; 

    (2) Early detection of lung cancer and esophageal cancer; (3) Mechanism of cancer metastasis

    Education

    (1) 1999.9—2004.6 Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong Province, China (Ph.D)

    (2) 1994.9—1999.6 Sun Yat-sen University of Medical Sciences (now known as Sun Yat-Sen University Medical College), Guangzhou, Guangdong Province, China (M.D)

    Publications

    1. Hou X, Fu JH, Wang X, Zhang LJ, Liu QW, Luo KJ, Lin P, Yang HX*. Prophylactic thoracic duct ligation has unfavorable impact on overall survival in patients with resectable oesophageal cancer. Eur J Surg Oncol. 2014 May 22. pii: S0748-7983(14)00447-8. doi: 10.1016/j.ejso.2014.05.002. [Epub ahead of print]

    2. Yang HX, Feng W, Wei JC, Zeng TS, Li ZD, Zhang LJ, Lin P, Luo RZ, He JH, Fu JH. Support Vector Machine-Based Nomogram Predicts Postoperative Distant Metastasis for Patients with Oesophageal Squamous Cell Carcinoma. Br J Cancer. 2013 Sep 3;109(5):1109-16. 

    3. Hou X, Wei JC, Fu JH, Wang X, Zhang LJ, Lin P, Yang HX*. Proposed Modification of the Seventh American Joint Committee on Cancer Staging System for Esophageal Squamous Cell Carcinoma in Chinese Patients. Ann Surg Oncol. 2014 Jan;21(1):337-42. 

    4. Hou X, Wei JC, Wu JX, Wang X, Fu JH, Lin P, Yang HX*. Multidisciplinary modalities achieve encouraging long-term survival in resectable limited-disease esophageal small cell carcinoma. PLoS One. 2013 Jul 9;8(7):e69259. doi: 10.1371/journal.pone.0069259. 

    5. Yang HX*, Fu JH. Reply:Should we omit tumor location as a variable when staging esophageal squamous cell carcinoma in the Chinese population? Ann Thorac Surg. 2013 Jun;95(6):2210. doi: 10.1016/j.athoracsur.2013.03.053.

    6. Hou X, Wei JC, Xu Y, Luo RZ, Fu JH, Zhang LJ, Lin P, Yang HX*. The positive lymph node ratio predicts long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China. Ann Surg Oncol. 2013 May;20(5):1653-9

    7. Yang HX, Hou X, Liu QW, Zhang LJ, Liu JG, Lin P, Fu JH. Tumor location does not impact long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China. Ann Thorac Surg. 2012 Jun; 93(6):1861-6. PMID:22551848

    8. Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang LJ, Yang HX*. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers. EJSO. 2012;38(6):523-30. PMID:22440742

    9. Liang Y, Hou X, Cui Q, Kang TB, Fu JH, Zhang LJ, Luo RZ, He JH, Zeng YX, Yang HX*. Skp2 expression unfavorably impacts survival in resectable esophageal squamous cell carcinoma.J Transl Med. 2012;10(1):73. doi: 10.1186/1479-5876-10-73.PMID:22533738

    10. Yang HX, Wei JC, Xu Y, Liu JG, Lin P, Rong TH, Fu JH. Modification of nodal categories in the seventh American Joint Committee on cancer staging system for esophageal squamous cell carcinoma in chinese patients. Ann Thorac Surg. 2011 Jul;92(1):216-24. PMID: 21718847 

    11. Li Y, Yang HX, Luo RZ, Zhang Y, Li M, Wang X, Jia WH. High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg. 2011 May;91(5):1531-8. PMID: 21524463

    12. Yang HX, Ling L, Zhang X, Lin P, Rong TH, Fu JH. Outcome of elderly patients with oesophageal squamous cell carcinoma after surgery. Br J Surg. 2010;97(6):862-7. PMID: 20301165

    13. Yang HX, Xu Y, Fu JH, Wang JY, Lin P, Rong TH. An evaluation of the number of lymph nodes examined and survival for node-negative esophageal carcinoma: Data from China. Ann Surg Oncol. 2010 Jul;17(7):1901-11. PMID:20146101

    14. Yang HX, Hou X, Lin P, Yang H, Zeng CG, Rong TH, Fu JH. Peripheral direct adjacent lobe invasion non-small cell lung cancer has a similar survival to that of parietal pleural invasion T3 disease. J Thorac Oncol. 2009;4(11):1342-6.PMID: 19861903

    15. Yang HX, Hou X, Lin P, Rong TH, Yang H, Fu JH. Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer. Ann Thorac Surg. 2009;88(2):372-8.PMID: 19632375

    Zhang Xu
    Title Associate Professor
    Profile
    Dr. Zhang Xu is the associate professor of surgery . He has been working in the Department of Thoracic Surgery, Cancer Center, Sun Yet –Sen University for 17 years after graduated from Sun Yet-Sen University of Medical Science in July 1997. He is very familiar with the diagnosis and treatment of thoracic tumor including carcinoma of lung, esophagus, breast cancer and mediastium. The responsibilities include :esophagoscopy, tracheoscopy, endscopic ultrasonography (EUS),thoracoscopy, mediastinoscopy,lobectomy, pneumoectomy, mediastinal lymph node dissection(opening or VATS),Lobar bronchoplasty,e sophagectomy with intrathoracic or cervical anastomosis(opening or VATS),mediastinal tumor resection,tumor of chest wall resection and reconstruction,radical and modified mastectomy,multidisciplinary management of cancer of lung and esophagus. Dr. Zhang has published more than 30 research papers.
    Email zhangxu@sysucc.org.cn
    Phone (8620) 87343258
    Research Interest(s)

    1. Detecting the related genes in esophageal carcinoma.

    2. Multidisciplinary management of cancer of lung and esophagus.3. The pattern of lymph node metastasis in esophageal carcinoma

    Education

    1986 - 1992   First High School of Puning, Gaungdong Province. 

    1992 - 1997   Sun Yet-Sen University of Medical Science ( now Sun Yet-Sen University ), Bachelor of Clinical Medicine 

    2001 – 2004  Sun Yet-Sen University, Master of Oncology 

    2005 – 2008  Sun Yet-Sen University, PhD of Oncology

    Publications

    1.  Zhang X, LinP, ZhuZH, LongH, WenJ, YangH, ZhangX, WangDF, FuJH, FangY, RongTH. Expressionprofiles of early esophageal squamous cell carcinoma by cDNA microarray[J]. Cancer Genet Cytogenet . 2009, 194(1):23-29.

    2.   Zhang X, ChenSB, ChenJX, WenJ, YangH, XieMR, ZhangY, HuYZ, LinP. CK19 mRNA expression in the bone marrow ofpatients with esophageal squamous cell carcinoma and its clinical significance[J]. Dis  Esophagus. 2010,23(1):437-443

    3.  Gao YH, Zhang X, An X, Cai MY, Zeng ZF, Chen G, Kong LH, Lin JZ, Wan DS, Pan ZZ, Ding PR. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locallyadvanced rectal cancer[J]. Strahlenther Onkol. 2014, 190(2): 158-164.(Co first author)

    4.   Zhang X, ZhuZH, LinP, YangH, FuJH, ZhangLJ, LongH, WenJ, HuangXP, FangY, RongTH. Analyzing the profile of chromosomal imbalances in esophageal atypical hyperplasia and early stage esophageal squamous cell carcinoma by 250K Snp Array[J]. ZhonghuaYi Xue Za Zhi. 2008,88(37):2636-2641.

    5.   Zhang X, Rong TH, Wu QL, Fu JH, Long H,Zhang LJ, Ma GW, Su XD, Li XD, Wang DF, Hu Y, Yang H. Differential diagnosis andtreatment of esophageal stromal tumors and smooth muscle tumors

    6.   Zhang X, Hung XP, Ma GW. Cyclin D1 expression in esophageal cancer and its clinical significance[J]. Journalof Sun Yat-Sen University. 2006,27(6):657-660.

    7.   Zhang X, RongTH, ZhangY, LongH, FuJH, LingP, ZhangLJ, YangMT, ZengCG, MaGW, SuXD, LiXD, WangJY, WenZS, ZhaoJM. Expression and significance of C-kit and platelet-derivedgrowth factor receptor-beta (PDGFRβ) in esophageal cancer[J]. Ai Zheng. 2006, 25(1):92-95.

    8.   Zhang X, Huang XP, Ma GW. Investigation of the key gene in 8q24 amplifications in esophageal cancer[J]. Chin J Oncol. 2007, 34(13):724-727.

    9.   Zhang X, Rong TH, Fu JH. Diagnosis and treatment of esophagealleiomyosarcomas[J]. Chinese Journal of Clinical Oncology andRehabilitation. 2005,12(5):452-454.

    10.  ZhangX, Huang XP, FuJH, LingP, ZhangLJ, YangMT, ZengCG, MaGW.Flake endonuclease expression in esophageal squamous cell carcinoma and itsclinical significance[J].Guoji Zhong Liu Xue Za Zhi. 2007,34(11):876-878.

    11.  Liang YJ, Zhang X, Dai CL, Zhang JY, Yan YY, Zeng MS, Chen LM, Fu LW.Bullatacintriggered ABCB1-overexpressing cell apoptosis via the mitochondrial-dependentpathway[J]. JBiomed Biotechnol. 2009:867123.

    12.  ZhouWJ, Zhang X, ChengC, WangF, WangXK, LiangYJ, ToKK, ZhouW, HuangHB, FuLW.Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein[J]. Br J Pharmacol. 2012,166(5):1669-1683.

    13.  XieMR, Zhang X, LinP, LinYB, RongTH, ZhangLJ, WenZS, LiXD.Short and long-term outcomes of neoadjuvant chemotherapy for locally advancedesophageal carcinoma [J]. ZhonghuaYi Xue Za Zhi. 2009,89(41):2906-2909.

    14.  HuangXP, Zhang X, SuXD, MaGW, ZhaoJM, RongTH.Expression and significance of MCM4 in esophageal cancer [J]. Ai Zheng. 2007, 26(1):96-99.

    15.  Xie MR, Zhang X, Lin P, Chen JX, Ling YB, Fu JH, Rong TH, Zeng CG, Huang ZF.Safety and long-term outcome of sleeve lobectomy for non-small cell lungcancer[J]. Ai Zheng. 2009,28(8):868-871.

    16.  Yan YY, Zheng LS, Zhang X, Chen LK, Singh S, Wang F, Zhang JY, Liang YJ, Dai CL, Gu LQ, Zeng MS, T Talele T, Chen ZS, Fu LW. Blockade of Her2/neubinding to Hsp90 by emodin azide methyl anthraquinone derivative inducesproteasomal degradation of Her2/neu[J].Mol Pharm. 2011,8(5):1687-1697.

    17.  LaiRC, WangXD, Zhang X, LinWQ, RongTH. Heart fatty acid-binding protein may not be an early biomarker for anthracycline-induced cardiotoxicity inrabbits[J]. Med Oncol. 2012,29(3):2303-2308..

    18.  YangHX, LingL, Zhang X, LinP, RongTH, FuJH. Outcome of elderly patients withoesophageal squamous cell carcinoma after surgery[J]. Br J Surg, 2010, 97(6): 862–867.

    19. SuX, MaG, Zhang X, LongH, RongTH. Surgical approach and outcomes for treatment ofpulmonary metastases[J]. AnnThorac Med, 2013,8(3):160-164.

    20.  WangXW, WangXK, Zhang X, LiangYJ, ShiZ, ChenLM, FuLW. FG020326 sensitizedmultidrug resistant cancer cells to docetaxel-mediated apoptosis viaenhancement of caspases activation[J]. Molecules. 2012,17(5):5442-5458.

    21. Liao H, Rao H, ZhangX, Lin Y, Jie M, Fu J, Long H, Rong T, Lin P.Retrospective study ofclinicopathological characteristics in bronchopulmonary carcinoid[J]. Zhongguo Fei Ai Za Zhi, 2010 ,13(6):591-597.

    22.  ChenLM, LiYF, Zhang X, YanSL, LiangYJ, FuLW.Reversal of multidrug resistance of tumor cells by FG020327 and itsmechanism[J]. Ai Zheng. 2005,24(2):189-193.

    23.  Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Zhang X, Li YF, Fu JH. Establishment andbiological analysis of the EC109/CDDP multidrug-resistant esophageal squamouscell carcinoma cell line [J]. OncolRep. 2009, 22(1):65-71.

    24.  Dai CL, Liang YJ, Chen LM, Zhang X, Deng WJ, Su XD, Shi Z, Wu CP, Ashby CR Jr, Akiyama S, Ambudkar SV, Chen ZS, Fu LW.Sensitizationof ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 viabinding to ABCB1 and inhibiting its function[J]. BiochemPharmacol. 2009,78 (4):355-364.

    25.  Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, Liang YJ, Mi YJ, To KK, Fu LW. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells[J]. Biochem Pharmacol. 2012,83(5):586-597.

    26.  DaiCL, XiongHY, TangLF, Zhang X, LiangYJ, ZengMS, ChenLM, WangXH, FuLW.Tetrandrine achieved plasma concentrations capable of reversing MDR in vitroand had no apparent effect on doxorubicin pharmacokinetics in mice[J]. Cancer Chemother Pharmacol. 2007 , 60(5):741-750.

    27.  Li-sheng Zheng, Fang Wang , Yu-hong Li, Xu Zhang, Li-ming Chen, Yong-ju Liang, Chun-ling Dai,Yan-yan Yan,Li-yang Tao, Yan-jun Mi, An-kui Yang, Kenneth Kin Wah To, Li-wu Fu. Vandetanib(Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance byInhibition of Their Transport Function[J]. PLoS One. 2009, 4(4):e5172.

    28.  Wen J, Zheng B, Hu Y, Zhang X, Yang H, Li Y, Zhang CY, Luo KJ, Zang X, Li YF, Guan XY, FuJH. Comparative proteomic analysis ofthe esophageal squamous carcinoma cell line EC109 and its multi-drug resistantsubline EC109/CDDP [J]. Int JOncol .2010, 36(1): 265-274.

    29. Lai RC, Long YH, Li QL, ZhangX, Rong TH. Oxidative stress markers may not be early markers ofdoxorubicin-induced cardiotoxicity in rabbits[J].Exp Ther Med 2011, 2 (5): 947-950

    30.  ZhaoXQ, XieJD, ChenXG, SimHM, Zhang X, LiangYJ, SinghS, TaleleTT, SunY, AmbudkarSV, ChenZS, FuLW. Neratinib reversesATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, invivo, and ex vivo[J].Mol Pharmacol. 2012 ,82(1):47-58.

    31.  Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, ZhangX, Fu JH, Zhang LJ, Su XD, Wu QL, Ling P, Chen M, Xie ZM, Hu Y, Rong TH.Threeimmunomarker support vector machines-based prognostic classifiers for stage IBnon-small-cell lung cancer [J]. JClin Oncol.  2009, 27(7):1091-1099.

    32.  SituD, LongH, LinP, ZhuZ, WangJ, Zhang X, XieZ, RongT. Expression andprognostic relevance of CD44v6 in stage I non-small cell lung carcinoma [J]. J Cancer Res Clin Oncol. 2010,136 (8):1213-1219.

     

    Last Updated on: August 2014

    Su Xiao-Dong
    Title Associate Professor and advisor of master’s degree student
    Profile

    Dr. Su has been working in the department of thoracic surgery, SYSUCC since July 1993 after graduated from Sun Yet Sen University of Medical Science (now Sun Yet Sen University). His expertise includes: Diagnosis and staging of thoracic tumor including carcinoma of lung, esophagus and mediastium; Surgical treatment of carcinoma of lung, esophagus and mediastium; Management of postoperative complications; Multidisciplinary management of cancer of lung and esophagus.

    Email
    Phone
    Research Interest(s)
    A subtask of a national 863 project: study on new antibody for lung cancer.Inflammation and prognosis of early stage lung cancer.
    Education

    1987 –1993 Sun Yet-Sen University of Medical Science ( now Sun Yet-Sen University ) Bachelor of Medicine; 

    1999 – 2001 University Of New South Wales, Australia, Master of Community Medicine; 

    2003 – 2006 Sun Yet-Sen University, Ph.D of Oncology/ Surgical Oncology

    Publications

    1. Mediastinal lymph node dissection affects survival in patients with stage I non small cell lung cancer. The Thoracic and Cardiovascular Surgeon 2008,56(4):226

    2. (co-author)Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Res 2008;68(19):7905–14

    3. Impact of the number of resected and involved lymph nodes on the outcome in patients with stage II non small cell lung cancer. Chin J Oncol 2010:;32(6):436

    4. Study on histological heterogeneity of non small cell lung cancer. China Cancer 2008;17(12):36

    5. Impact of visceral pleural invasion on the prognosis of stage Ib non small cell lung cancer. Chin J Oncol. 2008,30(5):368.

    6. Correlations of novel histological classification of 82 thymoma patients to their clinical characteristic and prognosis. Chin J Cancer. 2005,24(11):1363 .

    7. Combined surgical treatment for limited small cell lung cancer :clinical analysis of 51 cases. Chin J Cancer 2003;10:1099-1101。

    8. An analysis of smoking status in the community in Guangzhou. China Cancer 2005,14(12):776.

    9. . Prediagnostic smoking and postoperative survival in lymph node-negative esophagus squamous cell carcinoma patients Cancer Sci 2012; 103: 1985–1988

    10. Surgical approach and outcomes for treatment of pulmonary metastases Ann Thorac Med 2013;8:160-4

    11. Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma. J Thorac Dis 2014;6(7):949.

    The second author:

    12. Clinical analysis of primary lymphoepithelioma-like carcinoma of the lung. Chin J Oncol 2008;30(1):72.

    13. Emodin azide methyl anthraquionoe derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage. Molecular Cancer Therapy 2008,7(6):1688

    14. Survival analysis of patients with stage II squamous cell carcinoma of the thoracic esophagus after esophagectomy. Chin J Cancer. 2008;27(2):113.

    15. Clinical analysis of 22 cases of esophageal adenosquamous carcinoma. Chin J Oncol 2009;31(4):302.

    16. Survival analysis of 220 patients with completely resected stage II non small cell lung cancer. Chin J Cancer 2010;29(5):538.

     

    Last Updated on: August 2014

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.